Etiology and Pathogenesis
The etiology of MDSs is not known. The association of MDSs with increasing age suggests genetic damage caused by hazardous exposure or inherited susceptibility. Risk factors include exposure to benzene and other solvents, diesel fuel, smoking, and immunosuppression. 3 Chemotherapy and radiation therapy are associated with therapy-related MDS (dealt with in a separate article). The pathophysiology of MDSs is complex and involves abnormalities in the regulation of cellular proliferation, maturation, and survival. 4 In AML, there is widespread support for the concept that its development requires at least 2 somatic gene alterations: one mutation to augment the rate of cellular proliferation or enhance cell survival (a class I mutation), usually constitutively activating a tyrosine kinase or a RAS family member, and another mutation impairing normal cellular differentiation (a class II mutation), usually deregulating a hematopoietic transcription factor or a transcriptional coactivator, such as homeobox family members or the components of core binding factor. 4 In AML, these types of somatic gene alterations include recurrent chromosome abnormalities detected by cytogenetics and other acquired mutations such as TP53, NRAS, KRAS, KIT, PTPN11, CEBPA, CSF1R (C-FMS), NF1, and BRAF point mutations and MLL partial tandem duplications. 5 Unfortunately, our understanding of the molecular pathology of MDSs remains considerably more primitive than our understanding of the biology of AML. 6 Recurrent chromosomal gains and losses such as deletion of chromosomes 5, 7, 13, and 20 and the sex chromosomes or trisomy 8 are common in MDSs; however, the majority of them remain pathogenetically obscure. A notable exception is the loss of 5q31-33, which has been recently linked to a culprit gene, RPS14, coding for a component of the 40S ribosomal subunit and involved in the erythroid differentiation. 7 The informative reciprocal translocations, such as those that have led to a prognostically relevant subgrouping in AML, are rare in MDSs. Only a few uncommon MDS-associated rearrangements have been identified and further characterized, such as those involving 3q26 (corresponding to the zinc finger DNA binding protein, MDS1-EVI1), 3q25.1 (the p53 regulator, MLF1), and 1p36 (PRDM16, formerly MEL1, another zinc finger transcription factor). 8 Notably, all 3 of these latter genes are involved in balanced translocations, which are observed in fewer than 5% of patients with an MDS. The point mutations detected in AML have also turned out to be uncommon in MDSs, with a notable exception of the deletions in mitochondrial DNA. 5, 9, 10 Despite these limitations, chromosomal abnormalities in MDSs detectable by conventional karyotyping are clinically important. 1, 2 An abnormal karyotype can prove clonality, helping in establishing a diagnosis of MDS by ruling out, eg, a reactive pathogenesis. Karyotypic information is prognostically useful, 11 and, in the case of deletions of chromosome 5q, knowledge of the karyotype can even help in selecting a specific treatment, lenalidomide. 12 To enhance the detection of cytogenetic or genetic anomalies, fluorescence in situ hybridization (FISH) analysis as well as other karyotype based techniques (eg, spectral karyotyping) can be successfully used. In addition, recent evidence has shown that high-resolution single-nucleotide polymorphism Affymetrix (Santa Clara, CA) genotyping microarrays represent an effective technique for detecting cytogenetically cryptic genomic aberrations. 13, 14 This and other sensitive approaches may, in the future, allow stratification of patients for early therapeutic interventions. So far, however, treatment of MDSs is tailored to the clinical manifestations that predominate in an individual patient and that are responsible for the disease-associated morbidity. Nevertheless, select new therapies such as drugs inducing DNA hypomethylation such as 5-azacitidine and 5-aza-2′-deoxycitidine have shown promising results. 15 In addition to the acquired intrinsic genetic defects of hematopoietic stem cells, a proportion of patients with MDSs exhibit T cell-mediated inhibition of hematopoiesis and, because of that, may respond well to immunosuppression. In these cases, MDSs share similar pathophysiology with acquired aplastic anemia (AA).
Diagnostic Workup
The diagnostic workup of MDSs includes morphologic evaluation of peripheral blood, marrow aspirate, and bone marrow biopsy specimens, interpreted in the context of the CBC results and adequate clinical information. 1, 2, 16 As previously mentioned, correlation with marrow cytogenetics is essential. It needs to be emphasized, however, that the presence of a normal karyotype does not exclude a diagnosis of an MDS. Conversely, an abnormal karyotype may indicate an MDS within an appropriate clinical context.
Morphologic Features
Although an MDS can be suspected from the clinical history and the peripheral blood counts, the diagnosis is usually made by morphologic inspection of the peripheral blood, bone marrow aspirate, and bone marrow biopsy specimen. 1, 2 The previously used French-American-British (FAB) classification 17 was based entirely on findings identifiable by cytologic analysis of stained smears of peripheral blood and bone marrow aspirate. The main criteria for subclassification of MDSs were the percentage of blasts in the peripheral blood and bone marrow aspirates and the presence of dysplastic changes in at least 1 of the 3 main marrow cell lines. A more comprehensive approach is the one used by the current World Health Organization (WHO) system, which stresses the importance of integrating other techniques such as bone marrow biopsy histologic examination, cytogenetics, and molecular genetics, in the light of relevant clinical information. Morphologic dysplasia is not necessarily synonymous with an MDS, and, in part to address the issue of "false-positive" myelodysplasia, the WHO classification system recommends that at least 10% of the cells in a lineage be morphologically dysplastic to declare a dysplasia of this lineage. 1, 2 The currently used WHO classification of MDSs is principally based on the percentage of blasts in the bone marrow and peripheral blood and the type and degree of dysplasia. In particular, the extent of dysplasia, unilineage vs multilineage, has an important role in the WHO subclassification, a feature not considered in the FAB system. 17 In addition, the presence of ring sideroblasts is assessed by iron staining. The absence of monocytosis (monocytes, <1,000/µL [1 × 10 9 /L] in the blood; no monocytosis in the bone marrow [<5% monocytes; normal range, 0%-4%]) is important to distinguish between MDSs and chronic myelomonocytic leukemia, a subtype of myelodysplastic/ myeloproliferative neoplasm (MDS/MPN) formerly considered to belong to the MDS category. Monocytes in the bone marrow are best appreciated by using nonspecific esterase stains (recommended is the a-naphthyl butyrate esterase). 18 
Blasts
The enumeration of blasts is important for the diagnosis and classification of MDSs, and, in most studies, the blast percentage is one of the most important prognostic indicators. 1, 2 It is also an integral component of currently used prognostic scoring systems such as the International Prognostic Scoring System 11 and the more recent WHO classification-based prognostic scoring system. 19 Blasts should be carefully enumerated from well-prepared peripheral blood smears and bone marrow aspirate smears. Immature cells to be included in the blast count include myeloblasts-without and with a few fine azurophilic granules-monoblasts, and megakaryoblasts. Promonocytes are also considered as "blast equivalents" in the WHO classification scheme. 1 These cells, which in the absence of cytochemistry for esterase are morphologically difficult to distinguish from promyelocytes and early myelocytes, are rarely found in MDSs. Their presence suggests a diagnosis of chronic myelomonocytic leukemia or, in the presence of an increased blast count, AML with monocytic differentiation.
The blast count derived from the aspirate smears should be carefully correlated with the estimate from the biopsy sections. 1, 2, [20] [21] [22] Often, in the marrow biopsy specimen, blasts may be hard to appreciate, particularly if there is marrow fibrosis. In such cases, an immunohistochemical stain for CD34 antigen may be very helpful. [22] [23] [24] [25] [26] However, because not all blasts are CD34+, care must be taken not to use the CD34 result in lieu of careful morphologic assessment. Additional markers can be used to facilitate the visibility of CD34-blasts (eg, CD117, lysozyme, CD68). Myeloperoxidase is often weak or negative in blasts seen in MDSs. Flow cytometry may help in assessing the frequency of marrow blasts and to confirm their immunophenotype. In addition, aberrant antigen expression and side scatter abnormalities (owing to low granularity in the granulocytic cells) have also been shown to roughly correlate with the severity of the MDS.
Classification of MDS
The concept of the WHO system is that classification of hematopoietic neoplasms should be based not only on morphologic findings but also on the use of clinical, genetic, immunophenotypic, and biologic information to define separate disease entities. 1 However, because a single biologic or genetic marker that reliably identifies all or most cases of MDS has not yet been discovered, bone marrow morphologic assessment remains the most important tool for classifying the majority of cases of MDS.
Although concordance in the diagnosis of MDSs is generally reported to be approximately 80%, this only applies to cooperative clinical trials. Outside this setting, concordance among different observers is often considerably lower. 27 The factors that are largely responsible for inconsistencies in the diagnosis and classification include the variability in the quality of specimens, inaccurate enumeration of blasts, and the erroneous inclusion in the MDS category of cases with nonclonal dysplastic hematopoiesis or with other types of myeloid neoplasms (eg, MDS/MPN). Therefore, the importance of a critical evaluation of morphologic features in the light of other laboratory results and clinical information cannot be overemphasized.
The WHO Classification of the Myelodysplastic Syndromes (2008 Revision, 4th ed) has been recently published. 28 The updated classification, which largely overlaps with the 2001 WHO scheme, 1 distinguishes the following MDS subtypes: (1) refractory cytopenia with unilineage dysplasia with the subcategories of refractory anemia (RA), refractory neutropenia (RN), and refractory thrombocytopenia (RT); (2) refractory anemia with ring sideroblasts (RARS); (3) refractory cytopenia with multilineage dysplasia (RCMD); (4) refractory anemia with excess of blasts (RAEB) with subcategories RAEB-1 and RAEB-2; (5) MDS, unclassifiable; and (6) MDS with isolated del(5q) chromosomal abnormality. The main features of these subtypes are described in the following paragraphs and summarized in ❚Table 1❚.
Refractory Cytopenia With Unilineage Dysplasia
This designation encompasses the MDS cases that manifest with refractory cytopenia associated with dysplasia limited to 1 cell line and includes RA and the rare cases of RN and RT. Refractory bicytopenia may be included in this category if accompanied by unilineage dysplasia, but refractory pancytopenia that is associated with unilineage dysplasia should be considered MDS, unclassifiable.
The initial complaint is, in most cases, related to anemia (these cases are properly designated as RA). The anemia may be normocytic/normochromic but is often macrocytic. Blasts are absent in the blood or represent less than 1% of the differential count, and they account for fewer than 5% of the nucleated marrow cells. The marrow is usually hypercellular due to erythroid hyperplasia, and dyserythropoiesis is present, but ring sideroblasts account for fewer than 15% of the erythroid cells. Fewer than 10% of the cells in the granulocytic or megakaryocytic lineages show dysplasia. No Auer rods are present. The diagnosis is frequently one of exclusion; in the absence of cytogenetic abnormality, it requires cytopenia(s) of at least 6 months' duration and the exclusion of potential reactive causes. In cases characterized by anemia and dyserythropoiesis, conditions such as megaloblastic anemia and congenital dyserythropoietic anemia must be carefully excluded. In general, RA can be considered as a "low-grade" MDS with median survival in the range of 6 to 7 years and only 5% to 10% of cases progressing to overt acute leukemia.
RN and RT are very rare and likely account for fewer than 1% to 2% of all MDS cases; extreme caution should be used in making such diagnoses.
Refractory Anemia With Ring Sideroblasts
RARS is an MDS characterized by unexplained anemia, morphologic dysplasia of the erythroid lineage, and ring sideroblasts constituting 15% or more of the erythroid precursors. There is no significant granulocytic or megakaryocytic dysplasia (<10%). Anemia is the principal finding. The RBCs often exhibit a "dimorphic" pattern of normochromic and hypochromic cells, but macrocytosis is frequently observed as well. The criteria are similar to those described for RA, except that in the bone marrow, ring sideroblasts account for 15% or more of the erythroid precursors.
RARS is a low-grade process. In most series, it is reported to have the best prognosis and lowest rate of conversion to AML of all MDS subtypes. A median survival of 7 to 9 years or longer is commonly reported, and the conversion rate to acute leukemia is less than 5%. It must be remembered that ring sideroblasts can be found in any of the subsets of MDSs and also in AML. Furthermore, they may be seen in nonneoplastic diseases as well. In some cases, such as in the Pearson syndrome, ring sideroblasts result from abnormalities (mutation or deletion) of mitochondrial DNA that is important in regulating iron metabolism. 29 Whether some patients diagnosed with RARS who have no evidence of a cytogenetic abnormality may have ring sideroblasts due only to mitochondrial DNA abnormalities and no clonal genomic abnormalities is not clear. In rare patients, the platelet count is elevated (≥450 × 10 3 /µL [450 × 10 9 /L]), sometimes to more than 1,000 × 10 3 /µL (1,000 × 10 9 /L), and the differential diagnosis between RARS and a myeloproliferative disorder such as essential thrombocythemia becomes problematic. If the platelet count is 450 × 10 3 /µL (450 × 10 9 /L) or greater and the megakaryocytes have features of those described in the MPNs, an analysis for a JAK2 mutation is indicated. Most of these cases may be assigned to the provisional entity of RA with ring sideroblasts and thrombocytosis, 30 which is currently considered within the MDS/MPN group.
Refractory Cytopenia With Multilineage Dysplasia
This subcategory is an addition in the WHO classification of MDSs that was not recognized in the FAB system, and its identification has improved the prognostic usefulness of the morphologic classification of MDSs. [31] [32] [33] [34] [35] [36] [37] [38] RCMD is characterized by 1 or more cytopenias in the peripheral blood and dysplastic changes in 2 or more of the myeloid lineages: erythroid, granulocytic, and/or megakaryocytic. There are fewer than 1% blasts in the blood and fewer than 5% in the bone marrow. Auer rods are not found. If 15% or more of the erythroid precursors are ring sideroblasts the designation of RCMD with ring sideroblasts can be made, although reportedly there is no significant prognostic impact if ring sideroblasts are found. Cases that meet the criteria for RCMD but that have persistently 1% blasts in the blood should be considered MDS, unclassifiable, and those with multilineage dysplasia and fewer than 5% blasts in the bone marrow but 2% to 4% blasts in the blood should be classified as RAEB-1. Patients with RCMD have a worse outcome (reported median survival of 17-33 months) than patients with RA. 
Refractory Anemia With Excess of Blasts
RAEB is an MDS with 5% to 19% blasts in the bone marrow or blood. However, if there are fewer than 5% blasts in the bone marrow, the finding of 2% to 4% blasts in the peripheral blood is sufficient for the diagnosis of RAEB-1. Two subcategories are recognized: RAEB-1, defined as having 5% to 9% blasts in the bone marrow or 2% to 4% in the blood, and RAEB-2, when blasts are 10% or more in the marrow and/or 5% or more in the blood. Patients with RAEB-2 have worse survival and a higher rate of disease transformation to AML. RAEB is a serious disorder, regardless of whether it transforms to overt acute leukemia. The median survival time is less than 2 years in most series, and although 30% to 40% of patients develop overt acute leukemia, more will die of the complications of neutropenia, thrombocytopenia, or anemia than of acute leukemia. Median survival time for RAEB-1 is approximately 18 months vs 10 months for RAEB-2.
MDS Associated With an Isolated del(5q) Chromosomal Abnormality
This subtype of MDS is characterized by anemia with or without other cytopenias and a sole cytogenetic abnormality of del(5q). Myeloblasts constitute fewer than 5% of nucleated bone marrow cells and fewer than 1% of peripheral blood leukocytes. Auer rods are not seen. An interstitial deletion of the long arm of chromosome 5 is common in MDSs. Among cases with isolated del(5q), it is important to distinguish a unique clinicopathologic entity of the 5q-syndrome seen predominantly in older women. This syndrome is characterized by macrocytic anemia, normal or elevated platelet count, megakaryocytes with monolobated or hypolobated nuclei, fewer than 5% blasts, and a relatively good prognosis. An approximately 10-to 15-Mb commonly deleted region at 5q31 has been established. 39 There are several other regions that are deleted in patients with other types of MDS and AML, but deletions between bands 5q21 and 5q32 are limited to this syndrome. The critical gene(s) in this syndrome may thus be different from the genes associated with deletions of 5q found in other types of MDSs or AML. Recently, a defect in ribosomal protein function due to haploinsufficiency of RPS14 has been implicated in the pathogenesis of the 5q-syndrome. 7, 40 Patients with isolated del(5q) have a very favorable response to the drug lenalidomide. 12 
MDS, Unclassifiable
This subtype encompasses cases that do not fit easily into the other categories of MDS. Three possible situations that qualify for this diagnosis include (1) cases that fit the criteria for a diagnosis of refractory cytopenia with unilineage dysplasia or RCMD but in which a percentage of 1% blasts in the blood is found on at least 2 occasions, (2) MDS with morphologic unilineage dysplasia associated with pancytopenia, and (3) cases with persistent cytopenias lacking diagnostic morphologic features of MDSs (<10% dysplastic cells in any lineage) but with cytogenetic abnormalities considered as presumptive evidence of an MDS.
Prognostic Considerations
MDSs display impressive clinical heterogeneity running the gamut from an indolent disease with a near-normal life expectancy to an aggressive malignancy overlapping with AML. Following the original 1982 FAB classification scheme, 17 various additional systems have been proposed to improve prognostic predictive power in MDSs. In 1997, Greenberg et al 11 developed the International Prognostic Scoring System, based on bone marrow blast percentage, prognostically relevant cytogenetic abnormalities, and number of cytopenias. In 2001, the FAB guidelines were revised, and their updated version was integrated into the WHO classification system, which is currently in use worldwide. 1, 28 More recently, transfusion dependency has been shown to have a significant effect on survival of patients with MDSs. The integration of transfusion dependency within the WHO system has produced the so-called WHO classification-based prognostic scoring system. 19 
The MDS Section of the Workshop
The 2007 Society for Hematopathology/European Association for Haematopathology Workshop on Myeloid Neoplasms and Mastocytosis included a total of 16 cases in the MDS section. This section illustrated important diagnostic issues in relation to MDSs and included cases of the disease associated with isolated del(5q) chromosomal abnormality, including the "classical" 5q-syndrome and other MDS entities with isolated del(5q). Other issues raised by submitted cases included cytogenetic abnormalities (other than 5q abnormalities) seen in MDSs, the role of cytogenetics on its own in diagnosing MDSs, and problems in relation to the differential diagnosis of MDS vs rare subtypes of AML, particularly acute panmyelosis with myelofibrosis and erythroleukemia. The association and eventual relation of MDSs with paroxysmal nocturnal hemoglobinuria (PNH), AA, and other nonneoplastic disorders were also illustrated by several cases and addressed in the discussion. The main topics and the cases that illustrated them are summarized herein.
MDS Associated With Isolated del(5q) and the Association of del(5q) With Other Conditions
Isolated deletions of the long arm of chromosome 5, del(5q), are observed in 10% of MDSs. They are associated with a more favorable prognosis, although the clinical course varies considerably. If 1 or more additional chromosomal aberrations are present, the overall survival is significantly shorter. Case 141 illustrated a classic example of 5q-syndrome with a typical clinical picture and morphologic findings.
The workshop included 2 cases that demonstrated the association between the occurrence of an MDS with isolated del(5q) and lymphoid neoplasms. Case 36 illustrated a patient with a long history of chronic lymphocytic leukemia, later given a diagnosis of an MDS with an isolated 5q-abnormality. The bone marrow morphologic findings, which included a multinodular/interstitial small lymphoid cell infiltration and predominance of monolobated megakaryocytes are shown in ❚Image 1A❚ and ❚Image 1B❚. By FISH, the 5q-abnormality was detected only in granulocytes, while trisomy 12 was detected only in lymphocytes ❚Image 1C❚. The coexistence of an MDS and chronic lymphocytic leukemia is rare. In a large series, only 1% of the untreated patients diagnosed with MDS had also a B-cell malignancy. The association is most likely merely coincidental. 41 In patients with chronic lymphocytic leukemia previously treated with alkylating agents, a secondary MDS may be observed, although its occurrence is also uncommon despite extensive use of alkylating agents in this condition. 42 Case 85 illustrated the association of a plasma cell dyscrasia and an MDS, the latter associated with isolated del(5q). The bone marrow showed the presence of the typical nonlobated by flow cytometry at 8.4% of bone marrow cells) that were positive for CD34, CD7, CD33, HLA-DR, CD22, CD123, and CD135; had heterogeneous CD38 expression; and were negative for CD19, CD10, terminal deoxynucleotidyl transferase, CD13, CD117, and CD56. No response to lenalidomide was observed in this case. In AML, a 5q deletion is usually associated with a complex karyotype and is also associated with poor outcomes following treatment. 46 However, a small proportion of patients with a single del(5q) aberration and no antecedent hematologic disorder seem to have the same outcome as patients with a normal karyotype. 47 
MDS Diagnosed by Cytogenetics Alone and Other Cytogenetic Abnormalities Seen in MDS and Their Prognostic Value
Occasionally, one is confronted with patients who have persistent cytopenia (usually anemia) for which no underlying cause can be found but in whom there is insufficient morphologic evidence to support the clinical suspicion of an MDS. For some of these patients, a "working diagnosis" of idiopathic cytopenia of unknown significance may be considered, 48 although it is important to point out that this is not synonymous with a diagnosis of MDS. In such cases, it is necessary to explore every possible cause for the cytopenia(s) and to rule out disorders such as autoimmune disorders, lymphoproliferative diseases (particularly large granular lymphocyte proliferations and hairy cell leukemia), hypothyroidism and other endocrinopathies, and infections.
Immunohistochemical studies on biopsy specimens may reveal an increase in the number of blasts that was not appreciated previously, and they should always be performed. megakaryocytes ❚Image 2A❚ associated with an increased number of plasma cells, which could also be appreciated by their positivity on CD138 immunostaining ❚Image 2B❚. By flow cytometry, plasma cells expressed CD56 antigen. Case 7, submitted by Gerald Penn, MD, illustrated the coexistence of MDS (RCMD type) and plasma cell myeloma. Most of the cases reported previously in the literature included plasma cell myeloma, in which MDS was diagnosed after chemotherapy. 43 These were considered as clonally unrelated processes: the MDS was thought to be secondary to treatment with alkylating agents. The risk of both diseases has been estimated to be 10% to 20% after 10 years. 43, 44 Increased risk of secondary disease has been also reported in patients who received bone marrow transplantation (usually also pretreated with chemotherapy). 45 Less common are cases unrelated to therapy like the 2 cases presented in the workshop (cases 7 and 85).
In cases like these, in which no prior treatment is involved, the plasma cell tumor and MDS may arise from a common stem cell, which may be characterized by a common clonal cytogenetic abnormality. In this context, Nilsson et al 44 A different problem was illustrated by case 61, which was thought to represent a pediatric high-grade MDS associated with an isolated del(5q). The marrow flow cytometry ❚Image 3❚ showed a pathologic population of blasts (estimated To qualify a case as MDS-F, a silver-stained reticulin fibrosis score of 2 or more on the basis of the system proposed by Manoharan et al 55 should be obtained. Of note, up to 50% of therapy related-MDSs have marrow fibrosis as well. The marrow often shows trilineage dysplasia with prominent dysmegakaryopoiesis. In most cases, an increased number of blasts are seen; thus, most cases fall within the RAEB subgroup. The blasts are more easily documented in the marrow case 158 is not specifically characteristic of MDS, and that is why its presence was considered per se insufficient for establishing a diagnosis of MDS.
Case 192 was an example of a RCMD ❚Image 4❚ associated with t(6;9)(p23;q34). AML with t(6;9)(p23;q34) (DEK-NUP214) in adults and children has generally a poor prognosis, similar to other AMLs with unfavorable cytogenetic abnormalities. 49 Thus, the presence of a t(6;9) should raise prognostic concerns in this case, which morphologically would otherwise be consistent with a low-grade MDS (ie, not associated with an increased number of blasts). Thus, cases of t(6;9) with fewer than 20% blasts should be monitored closely for development of more definite evidence of AML. Case 161 was characterized by the presence of morphologic findings consistent with an RCMD with ring sideroblasts in association with an isolated del(20q). This cytogenetic abnormality, most often seen in cases with unilineage dysplasia (RA), is associated with indolent disease and minimal dysplastic changes and frequently manifests with anemia and thrombocytopenia. 50 The presence of multilineage dysplasia ❚Image 5❚ in the presence of a del(20q), as seen in this case, is, therefore, of unclear significance.
MDS With Fibrosis, APMF, and Other Fibrotic AML
About 5% to 10% of cases of MDS have significantly increased marrow reticulin fibers or even collagen fibrosis at diagnosis, [51] [52] [53] [54] and they are termed MDS with fibrosis (MDS-F). MDS-F is also characterized by severe pancytopenia. Organomegaly is minimal or absent. Overall, patients with MDS-F are reported to have shorter survival times than patients without this feature. 51, 52 ❚Image 4❚ (Case 192) Erythroid and granulocytic dysplasia in refractory anemia with multilineage dysplasia and t(6;9) (p23;q34). Contributed by G. Bhagat.
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❚Image 5❚ (Case 161) Refractory cytopenia with multilineage dysplasia and ring sideroblasts in a case with del(20q). A, Prominent erythroid dysplasia and rare dysplastic granulocytic precursors. B, Iron stain highlights ring sideroblasts. Contributed by F. Kreisel.
acute myeloid leukemia associated with a fibrotic bone marrow. 22 Classic myeloproliferative neoplasms, such as primary myelofibrosis (chronic idiopathic myelofibrosis), can be usually easily distinguished by their characteristic morphologic features (eg, large to giant megakaryocytes with cloud-like nuclei) and by the presence of significant splenomegaly and the lack of an abrupt presentation. 57, 58 Patients with MDS-F have an unfavorable prognosis mainly attributable to complications related to pancytopenia and continuous transfusions, with a life expectancy of 9.6 months, compared with 17.4 months in MDS without fibrosis. 52 An additional diagnostic problem was demonstrated by case 165. This case illustrates the difficulties encountered when attempting to separate RAEB-2 from acute erythroid leukemia. Although by the strict adherence to WHO criteria the case can be considered RAEB-2, the acute presentation, complex underlying karyotype, and, above all, the increased numbers of pronormoblasts ❚Image 8A❚ and ❚Image 8B❚, confirmed by immunohistochemical analysis ❚Image 8C❚ and flow cytometry, raised the issue of transformation to acute erythroid leukemia (pure erythroid subtype). The WHO criteria for acute erythroid leukemia can be summarized as follows: if the overall percentage of blasts is 20% or more, the diagnosis is AML; if there are fewer than 20% total blasts and the erythroid precursors are 50% or more of all cells, the differential count of nonerythroid cells should be calculated. If blasts are fewer than 20% of nonerythroid cells, the diagnosis is usually RAEB-2. If blasts are 20% or more of nonerythroid cells, the diagnosis is erythroleukemia (erythroid/myeloidM6a). Even less reproducible is the separation with the pure erythroid leukemia subtype of acute erythroblastic leukemia biopsy (CD34 immunohistology is particularly helpful) than in the aspirate, the latter being frequently suboptimal owing to the presence of myelofibrosis. Only rare cases of RA with fibrosis have been reported. These cases seem to share the poor prognosis associated with the RAEB with fibrosis subtype.
Often, cases of MDS-F have prominent megakaryopoiesis, which is characterized by a wide spectrum of sizes of megakaryocytes, ranging from micromegakaryocytes to enlarged forms. The antibodies reactive with megakaryocytic antigens (eg, CD42b and CD61) can be used to facilitate the detection of the small dysplastic forms (micromegakaryocytes in particular) and to confirm the increased number of megakaryocytes. 51 The differential diagnosis of MDS-F includes several other myelofibrotic myeloid neoplasms. The differential diagnosis between MDS-F and acute panmyelosis with myelofibrosis (APMF) was illustrated by cases 75 and 191 ❚Image 6❚ and ❚Image 7❚. Both cases were eventually considered examples of MDS-F, specifically as RAEB-2 with fibrosis.
Clinically, APMF usually manifests with an abrupt onset with fever and bone pain and runs a very aggressive course. Morphologically, the marrow shows marked fibrosis (≥2 according to the Manoharan grading system), severe trilineage dysplasia associated with numerous dwarf megakaryocytes, and an increased number of blasts. Based on bone marrow biopsy, a median blast value of 22.5% (range, ~20%-25%) was reported. 56 Most of the blasts express CD34 and are negative for megakaryocyte-associated markers. 56 The differential diagnosis of APMF includes, besides MDS-F, acute megakaryoblastic leukemia and other types of Hypoplastic MDS (h-MDS) is more frequent in women and occurs with an age-related frequency similar to that seen in nonhypoplastic cases. Previous genotoxic exposure or therapy needs to be excluded because hypocellular marrows can also be seen in cases of therapy-related MDS. 64 Generally, h-MDS is associated with pronounced cytopenias, a finding that may suggest a diagnosis of acquired AA.
The diagnosis may be difficult, largely because fatty bone marrows usually produce poor quality aspirates. A careful inspection of peripheral blood smears and bone marrow touch preparations together with a detailed analysis of adequately representative bone marrow biopsy sections cannot be overemphasized. In this diagnostic context, megaloblastic features alone have insufficient specificity to establish a diagnosis of MDS because megaloblastic features and macrocytosis are common findings in AA as well. According to the FAB criteria, most cases of hypoplastic MDS can be classified (M6b), which was the alternative diagnostic consideration in this case. However, since there is an extensive overlap in cytogenetics between RAEB-2 and acute erythroblastic leukemia, it is uncertain if the distinction is clinically meaningful. The marrow cellularity is normal or increased for age in 90% of patients with MDS but is hypocellular in about 5% to 10% of the cases. 1, 11, [59] [60] [61] [62] Hypocellularity is defined as bone marrow cellularity of less than 30% in a patient younger than 60 years or less than 20% in patients older than 60 years. 63 In MDS, rarely the cellularity falls below 10%, which is in contrast with what is regularly seen in cases of severe AA. However, in these rare cases of MDS with markedly fatty marrow, the distinction from AA may be at times impossible. study of patients with PNH has shown that in this condition, cytogenetically abnormal clones are not necessarily malignant and may not be predictive of evolution to leukemia. 71 Distinctively uncommon is the association between MDS and pure red cell aplasia, as shown by case 124, submitted by Gang Yue, MD. The incidence of this association is probably underestimated. 72 Pure red cell aplasia may rarely be simulated by the presence of a 5q-abnormality, which should always be excluded. Although an immunologic basis (similar to hypoplastic MDS) had been hypothesized, the precise pathogenetic mechanism is unknown. Therapy with steroids does not help, and patients are often candidates for immunosuppressive treatment.
The Association and Eventual

Other Reactive Conditions
Morphologic myelodysplasia does not necessarily translate into a diagnosis of MDS. Vitamin B 12 and folic acid deficiencies lead to megaloblastic changes and often severe dyserythropoiesis, and such deficiencies must always be excluded before making a diagnosis of MDS, particularly RA. Heavy metal intoxication, particularly arsenic poisoning, and copper deficiency can induce marked and sometimes truly bizarre morphologic abnormalities in the erythroid and granulocytic series. 73, 74 A number of drugs and medications, ranging from alcohol to growth factors, can also induce myelodysplastic as RA (66. 7% in 1 series) . 60 The presence of 20% or more myeloblasts in a hypocellular marrow rules out MDS in favor of hypocellular AML. Dysplastic features other than dyserythropoiesis occur less frequently in hypoplastic MDS and/or are of lower grade in comparison with normocellular to hypercellular MDS. Because the patients do not have an increased proportion of blasts in the aspirate or in the bone marrow biopsy specimen, the separation from AA by morphologic criteria alone may be problematic. This is further compounded by the high proportion of cases showing a mesenchymal reaction, especially an increase in the number of mast cells and reactive lymphoid follicles, features similar to those observed in bone marrow biopsies obtained from patients with AA. Despite all of this, the differential diagnosis is still principally based on bone marrow histologic and immunohistologic features. Within the context of a markedly hypocellular bone marrow, the detection of "residual" megakaryopoiesis, particularly in association with dysmegakaryopoiesis, and the presence of dysgranulopoiesis (the latter in peripheral blood or marrow smears/touch preparations) support the diagnosis of h-MDS. If reticulin fibrosis is detected, this would also favor h-MDS.
Immunohistochemical analysis can help in distinguishing h-MDS from acquired AA, the former disorder being characterized by higher CD34 expression as compared with the latter. [60] [61] [62] Flow cytometry has shown similar findings in relation to CD34+ cells. 65 Finally, bone marrow cellularity does not appear to be an important prognostic factor in MDSs because patients with h-MDS have been shown to have a prognosis similar to that of patients with MDS with normocellular or hypercellular marrows. The distinction from AA, however, is significant because the risk of progression to acute leukemia is much greater in h-MDS than in the former disease. 66 Cytogenetic studies may be of particular value in this group as abnormalities of chromosomes 5 and/or 7 are frequently observed in hypocellular MDSs. The presence of other cytogenetic abnormalities (eg, trisomy 8) may not be discriminatory because it can also be observed in AA.
From a pathogenetic standpoint, however, it is important to stress that AA and MDSs have a number of overlapping features, such as the appearance of a clone of PNH cells 67, 68 and evidence of T cell-mediated myelosuppression that may respond to immunosuppressive therapy, suggesting that, at least in a proportion of cases, they share a common pathophysiologic mechanism. 69, 70 Case 131 represented an example of an MDS, a case of RCMD, associated with a PNH clone ❚Image 9❚. It is important to remember, however, that abnormal morphologic bone marrow features reminiscent of MDS are not uncommon in PNH marrows, and some of the cases of MDS with associated PNH clones may not represent an MDS. The presence of a karyotype abnormality may help in establishing the diagnosis of MDS in this context. However, caution should be used here, too. A relatively large HIV infection. Chronic parvovirus, Epstein-Barr virus, and cytomegalovirus infections have been associated with cytopenias and an array of dysplastic features in immunocompromised and nonimmunocompromised patients. Hemophagocytosis can rarely produce marrow changes that resemble those seen in MDS. Case 115 was an example of hemophagocytic lymphohistiocytosis (HLH) in a patient with a history of a low-grade MDS. Although the morphologic findings were considered compatible with HLH ❚Image 10❚, the diagnosis of MDS was not well substantiated. The distinction between HLH and MDS can be difficult owing to overlapping symptoms of pancytopenia. Clinically, HLH can be mistaken, especially in pediatric patients, for acute leukemia or an aggressive MDS. Bone marrow changes morphologically mimicking MDSs in patients with HLH have also been reported. [77] [78] [79] features. Congenital dyserythropoietic anemia may be difficult to distinguish from RA. 75 In each case with morphologic dysplasia, it is important to consider other possibilities.
In general clinical practice, it is important to remember that anemia associated with a high mean corpuscular volume and a low reticulocyte count may be seen in patients with hypothyroidism or liver failure. In most of these cases, the anemia is macrocytic but not megaloblastic, and the only feature similar to MDS is usually the presence of macrocytosis. Among the conditions associated with anemia and with other cytopenias most commonly seen in clinical practice, it is worthwhile mentioning autoimmune diseases (these can also cause myelofibrosis, an occurrence termed autoimmune myelofibrosis) and other hematopoietic neoplasms, eg, lymphomas, and nonhematopoietic malignancies causing paraneoplastic myelodysplasia. All of these can, to a certain extent, mimic the presentation of MDSs.
Viral disorders, particularly HIV infection, may be associated with myelodysplastic features. In HIV infection, like in MDS, cytopenias are common and the marrow is often hypercellular. Dyserythropoiesis is the most frequently reported myelodysplastic change and has been described in up to 70% of patients with HIV infection, but dysmegakaryopoiesis and dysgranulopoiesis have also been described. These cases may also show some fibrosis. However, the presence of cellular debris in association with an increased number of plasma cells and lymphocytes, which are frequently seen in bone marrows of HIV+ patients, are not usually seen in MDS. 76 Other viruses may cause dysplastic changes; these can be sometimes found "superimposed" on a myelopathic background associated with 
